Background {#Sec1}
==========

Gastric cancer (GC) is one of the most common cancers worldwide and remains the leading cause of cancer related death \[[@CR1]\]. The incidence of this disease varies with the geographical region and patient ethnicity. About 70% cases in the world were reported from developing countries, and Eastern Asian countries have the highest GC incidence and mortality \[[@CR1], [@CR2]\]. Although mechanism of gastric carcinogenesis is still not fully understood, environmental factors, such as high intake of salt, tobacco smoking, and particularly *Helicobacter pylori*(*H. pylori*) infection have been regarded as the risk factors for the disease \[[@CR3]\].Genetic factors have also been found to contribute to the risk of GC, with the first-degree relatives of the GC patients tending to have about 1.3 to 3.0 fold higher relative risk for GC than those without relatives with GC \[[@CR4]\].

To date, genetic variations have widely been shown to be associated with GC risk \[[@CR5]\], with particular importance on the polymorphisms involved in the signal transduction pathways \[[@CR6], [@CR7]\]. The 5-AMP-activated protein kinase (AMPK) pathway has been implicated in a series of tumors including GC. This is a heterotrimeric protein that consists of an α-catalytic subunit and 2 regulatory subunits (β and γ), and the α-subunit is encoded either by *PRKAA1* or *PRKAA2* gene. Previous genome-wide association study (GWAS) identified the *PRKAA1* polymorphism rs13361707 as a risk factor for non-cardiac GC (NCGC) in a Chinese population \[[@CR8]\]; however, these results were not successfully duplicated \[[@CR9]\], which may be due to the different characteristics of enrolled participants, population stratification, and clinical pathologic characteristics of GC. It is also not known whether the polymorphisms in the *PRKAA1* gene are related to clinical pathological characteristics of GC and clinical outcome of the patients. We carried out this case-control study on a Chinese population to investigate the susceptibility of six polymorphisms in the *PRKAA1* gene (see Additional file [1](#MOESM1){ref-type="media"}.) to the risk of GC and their associations with the clinical pathological characteristics, and evaluated the predictive value of these polymorphisms to the clinical outcome of GC patients.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

A total of 481 GC patients, and age- and gender-matched 490 healthy individuals were enrolled in this study. The patients were histologically diagnosed as GC from Nanjing First Hospital, Nanjing Medical University, and the healthy controls were individuals who came to the hospital for routine physical examinations and were confirmed be healthy. All the participants were the heritably unrelated ethnic Han Chinese from the same geographic region of Nanjing City, Jiangsu, China. The whole blood of all enrolled participants were collected before operation and then stored at − 80 °C before genotyping. The clinical features of patients, including tumor size, distant metastasis, and depth of invasion, were collected from the patients' medical records provided by Department of pathology, and the tumor TNM stages were examined and evaluated using the TNM classification according to American Joint Commission for Cancer Staging in 2002, sixth edition. The clinical outcomes of patients were found through on-site interview, direct calling, or medical chart review.

The characteristics of healthy controls, including age, gender, smoking and drinking, were collected via a questionnaire. Individuals who had smoked daily for more than 1 year were considered smokers, and those who consumed one or more alcoholic drinks per week for at least one year were considered drinkers. The protocol of this study was in accordance with the Declaration of Helsinkiand approved by the Institutional Review Board of the Nanjing First Hospital, and written informed consent was obtained from all the participants.

DNA extraction and genotyping {#Sec4}
-----------------------------

The genotypes of all polymorphisms were detected with the SequenomMassARRAY platform, as previously described \[[@CR10], [@CR11]\]. First, DNA was extracted from whole-blood samples and concentrated by using GoldMag-Mini Whole Blood Genomic DNA Purification Kit according to the manufacture's protocol (GoldMag Co. Ltd. Xi'an, China), and then DNA purity was measured by spectrometry (DU530 U*V*/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, US). The qualified DNA samples were genotyped using the SequenomMassARRAY platform followed the standard protocol recommended by the manufacturer of a Sequenom Mass-ARRAY®RS1000(Sequenom, Inc.). Multiplexed SNP MassEXTENDED assay was designed by SequenomMassARRAY Assay Design 3.0 Software \[[@CR12]\]. Finally, data management and analysis were performed using SequenomTyper 4.0 Software \[[@CR12], [@CR13]\].

*H. pylori* infection detection {#Sec5}
-------------------------------

*H. pylori* infection status of enrolled participants has been determined by serology using a commercial *H. pylori* Immunogold Testing Kit (KangmeiTianhong Biotech (Beijing) Co., Ltd., Beijing, China), which has been validated in the Chinese population with sensitivity of 98.29% and specificity of 98.51% for the detection of *H. pylori* infection.

Statistical analysis {#Sec6}
--------------------

The Hardy-Weinberg equilibrium in the healthy control group was tested by using a goodness of fit chi-square test. The statistical analysis for genotype distribution was performed by the χ2 test, and odds ratios (OR) and 95% confidence intervals (CIs) were calculated using logistic regression model. The dominant model, co-dominant model, and additive model were the test for all polymorphisms, with the dominant and co-dominant models being used only if the additive model is significant or there is a previous hypothesis to do this.

Survival curves were analyzed by the Kaplan-Meier method, and the Hazard ration (HR) and 95% CIs were calculated using Cox proportional hazards regression model. The *P* value \< 0.05 was considered statistically significant difference. The haplotype analysis was performed using online software SHEsis ([analysis.bio-x.cn/myAnalysis.php](http://analysis.bio-x.cn/myAnalysis.php)).

Results {#Sec7}
=======

Characteristics of the participants {#Sec8}
-----------------------------------

There was no significant difference in age (cases: 65.55 ± 11.92 years, healthy controls: 64.85 ± 11.83; *p* = 0.694), gender (cases: male73.60%, healthy controls: male73.27%; *p* = 0.782), smoking (cases: 23.08%, healthy controls: 24.29%; *p* = 0.658), and drinking (cases: 11.02%, healthy controls: 9.59%; *p* = 0.465) between cases and controls. For *H. pylori* infection status, the ratio of *H. pylori* infection in cases (54.47%) was higher than that in healthy controls (49.18%), however there was no significant difference between the two groups (*p* = 0.099), as presented in Table [1](#Tab1){ref-type="table"}.Table 1Clinical characteristics of the participantsVariablesCases, n (%)Controls, n (%)*p*-ValueTotal481490Age (mean ± SD)65.55 ± 11.9264.85 ± 11.830.694^a^ \>601681670.782^b^  ≤ 60313323Gender Male354(73.60)359(73.27)0.907 ^b^ Female127(26.40)131(26.73)Drinking Yes53(11.02)47(9.59)0.465 ^b^ No428(88.98)443(90.41)Smoking Yes111(23.08)119(24.29)0.658 ^b^ No370(76.92)371(75.71)*Helicobacter pylori* infection status Positive262(54.47)241(49.18)0.099 ^b^ Negative219(45.53)249(50.81)Differentiation Low195(40.54) Med and high286(59,46)Clinical stages T1-T2159(33.06) T3-T4322(66.94)Tumor Site GCA140(29.11) NGCA341(70.89)*GCA* gastric cardiac adenocarcinoma, *NGCA* non-gastric cardiac adenocarcinoma^a^Independent *t*-test. ^b^Two-sided χ2 test for distributions between cases and controls

For the clinical pathological characteristics, a total of 195 (40.54%) and 286 (59.46%) patients had low and median to high pathological differentiation, respectively. For the tumor site classification, a total of 159 (33.06%) and 322 (66.94%) patients were classified to TNM stage T1-T2 and T3-T4, respectively. For the tumor location, a total of 140 (29.11%) and 341(70.89%) patients were diagnosed as gastric cardiac adenocarcinoma (GCA) and non-cardiatic GC (NCGC), respectively.

Association between polymorphisms and risk of GC {#Sec9}
------------------------------------------------

The genotype distributions of the selected polymorphisms in cases and controls are presented in Table [2](#Tab2){ref-type="table"}. The observed frequencies of all tested genotypes in controls did not deviate from Hardy-Weinberg equilibrium (HWE) (rs10074991: *p* = 0.129; rs13361707: *p* = 0.152; rs1044129: *p* = 0.368; rs154268: *p* = 0.140; rs6882903: *p* = 0.842; rs3805490: *p* = 0.929; rs461404: *p* = 0.155).Table 2Distribution of the genotypes in all participantsGenotypeControls, n (%)Patients, n (%)OR (95% CI)^a^*p*-Valuers10074991 AA128(26.12)104(21.62)Reference AG261(53.27)255(53.01)1.19(0.87,1.62)0.283 GG101(20.61)122(25.36)1.44(0.99,2.09)0.056 AG/GG362(73.88)377(78.38)1.26(0.94,1.70)0.127 Additive model1.21(1.01, 1.46)0.042rs13361707 TT129(26.33)103(21.41)Reference TC260(53.06)256(53.22)1.22(0.89,1.66)0.219 CC101(20.61)122(25.36)1.47(1.01,2.14)0.043 TC/CC361(73.67)365(75.88)1.29(0.96,1.74)0.093 Addictive model1.22(1.02,1.47)0.033rs154268 TT297(60.61)271(56.34)Reference TC176(35.92)179(37.21)1.13(0.86,1.47)0.388 CC17(3.47)31(6.44)1.96(1.06,3.63)0.033 TC/CC193(39.39)210(43.66)1.20(0.93,1.56)0.158 Additive model1.24(1.00,1.53)0.053rs6882903 CC342(69.80)312(64.86)Reference CA134(27.35)149(30.98)0.86(0.41,1.80)0.687 AA14(2.86)20(4.16)1.56(0.77,3.15)0.217 CA/AA148(30.20)169(35.14)1.26(0.96,1.65)0.097 Additive model1.23(0.98,1.55)0.078rs3805490 TT279(56.94)280(58.21)Reference TA181(36.94)170(35.34)0.93(0.71,1.21)0.567 AA30(6.12)31(6.44)1.02(0.60,1.73)0.953 TA/AA211(43.06)201(41.79)0.94(0.73,1.21)0.627 Additive model0.97(0.79,1.19)0.756rs461404 AA298(60.82)270(56.13)Reference GA175(35.71)179(37.21)1.14(0.87,1.49)0.341 GG17(3.47)32(6.65)2.05(1.11,3.78)0.022 GA/GG192(39.18)211(43.87)1.22(0.95,1.58)0.125 Additive model1.26(1.01,1.56)0.037^a^Adjusted for age, gender, smoking, drinking, and *Helicobacter pylori* infection

Rs10074991 GG genotype had a borderline significantly increased risk of GC (adjusted OR = 1.44, 95%CI: 0.99--2.09, *p* = 0.056), and the additive model shows rs10074991 is an increased risk factor for GC (adjusted OR = 1.21, 95%CI: 1.01--1.46, *p* = 0.042). In similar, an increased risk of rs13361707 was also observed for GC (TC vs. GG: adjusted OR = 1.47, 95%CI: 1.01--2.14, *p* = 0.043; additive model: adjusted OR = 1.22, 95%CI: 1.02--1.47, *p* = 0.033). Besides, the results have also revealed that rs154268 and rs461404 are associated with increased GC risk (rs154268 TC: adjusted OR = 1.96, 95%CI: 1.06--3.63, *p* = 0.033; rs154268 additive model: adjusted OR = 1.24, 95%CI: 1.00--1.53, *p* = 0.053; rs461404 GA: adjusted OR = 2.05, 95%CI: 1.11--3.78, *p* = 0.022; rs461404 additive model: adjusted OR = 1.26, 95%CI: 1.01--1.56, *p* = 0.037). However, there was no significant association between rs6882903 and rs3805490 and risk of GC, as summarized in Table [2](#Tab2){ref-type="table"}.

Stratification analysis {#Sec10}
-----------------------

To further assess the four potential susceptible polymorphisms (rs10074991, rs13361707, rs154268 and rs461404) to the risk of GC, a stratified analysis was performed by subgroups of participants' clinical characteristics (age, gender, *H. pylori* infection status), and tumor pathological characteristics (tumor site, tumor differentiation, and clinical stage).

In China, men usually retire at age of 60, which means they retain a stable and sustainable life style (the environmental factors), so we choose 60 years as the cut-off value for the subgroup analysis. In the subgroup of age ≤ 60, rs10074991GG (adjusted OR = 1.93, 95%CI: 1.00--3.73, *p* = 0.050), rs13361707CC (adjusted OR = 2.00, 95%CI: 1.04--3.84, *p* = 0.039) and rs461404GG (adjusted OR = 3.12, 95%CI: 1.05--9.28, *p* = 0.040) were associated with increased GC risk. However, in the group of age**\>**60, there was no significant association of these four polymorphisms with the risk of GC. For the subgroup of gender, in the male group, rs10074991 (additive model: adjusted OR = 1.25, 95%CI: 1.01--1.56, *p* = 0.046) and rs13361707 (CC: adjusted OR = 1.44, 95%CI: 1.01--2.06, *p* = 0.044; additive model: adjusted OR = 1.27, 95%CI: 1.02--1.58, *p* = 0.034) contributed to increased risk of GC. In similar, in the subgroup of positive *H. pylori* infection, a borderline significantly increased risk of rs10074991 (AG: adjusted OR = 1.68, 95%CI: 0.98--2.88, *p* = 0.060; additive model: adjusted OR = 1.30, 95%CI: 0.99--1.69, *p* = 0.057) and rs13361707 (TC: adjusted OR = 1.75, 95%CI: 1.02--3.00, *p* = 0.042; additive model: adjusted OR = 1.32, 95%CI: 1.01--1.73, *p* = 0.041) was observed for GC, as shown in Table [3](#Tab3){ref-type="table"}. For the subgroup of pathological characteristics of tumor, the four polymorphisms were significant associated with increased risk of NCGC, but not GCA. Moreover, the significant associations of these four polymorphisms were observed in the subgroup of patients with tumor in median or high differentiation or T3-T4, but not for low differentiation or T1-T2, as shown in Table [4](#Tab4){ref-type="table"}.Table 3*PRKAA1* Polymorphisms with Gastric Cancer Risk by Clinical Characteristics of ParticipantsGenotypeAgeSex*Helicobacter pylori* infection*.*≤60\>60MaleFemalePositiveNegativeCa/CoOR (95% CI)PCa/CoOR (95% CI)^a^PCa/CoOR (95% CI)^a^PCa/CoOR (95% CI)^a^PCa/CoOR (95% CI)^a^PCa/CoOR (95% CI)^a^Prs10074991 AA33/45Reference71/83Reference69/62Reference35/36Reference52/57Reference52/71Reference AG90/901.31(0.76,2.25)0.331165/1711.10(0.75,1.62)0.630197/1931.35(0.93,1.95)0.11758/680.77(0.42,1.41)0.399142/1391.12(0.72,1.75)0.613113/1221.26(0.81,1.96)0.302 GG45/321.93(1.00,3.73)0.05077/691.20(0.76,1.91)0.43688/741.51(0.97,2.37)0.07034/271.27(0.63,2.58)0.50368/451.68(0.98,2.88)0.06054/561.31(0.77,2.22)0.318 AG/GG135/1221.46(0.87,2.45)0.154242/2401.15(0.80,1.66)0.461285/2671.40(0.98,1.99)0.06792/950.91(0.52,1.59)0.734210/1841.26(0.82,1.93)0.292167/1781.27(0.84,1.94)0.255 Additive model1.40(1.01,1.93)0.0431.12(0.89,1.41)0.3321.25(1.01,1.56)0.0461.10(0.77,1.55)0.6111.30(0.99,1.69)0.0571.14(0.88,1.48)0.313rs13361707 TT33/46Reference70/83Reference68/93Reference36/35Reference51/58Reference52/71Reference TC90/891.35(0.79,2.33)0.273166/1711.12(0.76,1.65)0.563198/1921.40(0.96,2.03)0.08058/680.77(0.42,1.41)0.399143/1381.18(0.76,1.84)0.465113/1221.26(0.81,1.96)0.302 CC45/322.00(1.04,3.84)0.03977/691.22(0.77,1.94)0.40288/741.56(1.00,2.44)0.05234/271.27(0.63,2.58)0.50368/451.75(1.02,3.00)0.04254/561.31(0.77,2.22)0.318 TC/CC135/1211.51(0.90,2.53)0.119242/2401.17(0.81,1.69)0.408286/2661.44(1.01,2.06)0.04492/950.91(0.52,1.59)0.734211/1831.32(0.86,2.03)0.200167/1781.27(0.84,1.94)0.255 Additive model1.41(1.02,1.95)0.0361.13(0.90,1.42)0.3051.27(1.02,1.58)0.0341.10(0.77,1.55)0.6111.32(1.01,1.73)0.0411.14(0.88,1.48)0.313rs154268 TT92/106Reference179/191Reference195/213Reference76/84Reference151/146Reference120/151Reference TC64/561.32(0.83,2.10)0.241115/1201.03(0.74,1.44)0.844140/1340.81(0.60,1.10)0.35739/420.95(0.55,1.65)0.86691/861.03(0.71,1.49)0.89188/901.21(0.83,1.78)0.315 CC12/52.77(0.92,8.33)0.06919/121.63(0.76,3.51)0.21019/121,73(0.81,3.67)0.15312/52.44(0.82,7.29)0.11120/92.16(0.95,4.91)0.06811/81.77(0.69,4.55)0.238 TC/CC76/611.45(0.92,2.26)0.107134/1321.09(0.80,1.50)0.581159/1461.20(0.89,1.62)0.23051/471.12(0.67,1.87)0.668111/951.13(0.79,1.62)0.49699/981.27(0.88,1.84)0.208Additive model1.46(1.00,2.12)0.0481.13(0.87,1.48)0.3551.21(0.94,1.56)0.1421.23(0.82,1.85)0.3081.21(0.90,1.62)0.2011.26(0.92,1.73)0.153rs461404 AA91/106Reference179/192Reference195/214Reference75/84Reference151/146Reference119/152Reference GA64/561.34(0.84,2.13)0.218115/1191.05(0.75,1.45)0.792139/1331.16(0.85,1.58)0.34740/421.00(0.58,1.72)0.99191/861.03(0.71,1.49)0.89188/891.25(0.85,1.83)0.255 GG13/53.12(1.05,9.27)0.04019/121.64(0.76,3.53)0.20720/121.84(0.87,3.87)0.10912/52.46(0.82,7.36)0.10820/92.16(0.95,4.91)0.06812/81.96(0.77,4.97)0.156 GA/GG77/611.49(0.95,2.32)0.082134/1311.10(0.81,1.52)0.537159/1451.21(0.90,1.64)0.20552/471.16(0.69,1.93)0.573111/951.13(0.79,1.62)0.496100/971.31(0.91,1.90)0.150 Additive model1.51(1.04,2.19)0.0301.14(0.88,1.49)0.3271.23(0.95,1.59)0.1131.26(0.84,1.89)0.2611.21(0.90,1.62)0.2011.31(0.95,1.79)0.098^a^Adjusted for age, gender, smoking, drinking, and *Helicobacter pylori* infection; Ca, case; Co, controlTable 4*PRKAA1* Polymorphisms with Gastric Cancer Risk by Tumor ClassificationGenotypeCoSiteDIFTNMGCANGCALowMed-highT1-T2T3-T4CaOR (95% CI)^a^PCaOR (95% CI)^a^PCaOR (95% CI)^a^PCaOR (95% CI)^a^PCaOR (95% CI)^a^PCaOR (95% CI)^a^Prs10074991 AA12843Reference61Reference47Reference57Reference35Reference69Reference AG261730.80(0.51,1.24)0.3121821.45(1.01,2.09)0.0431041.09(0.73,1.63)0.6831511.28(0.88,1.86)0.203881.23(0.79,1.94)0.3621671.16(0.82,1.66)0.409 GG101240.66(0.37,1.16)0.150982.02(1.32,3.07)0.001441.17(0.71,1.93)0.528771.66(1.08,2.57)0.022361.33(0.77,2.29))0.308861.51(0.99,2.28)0.054 AG/GG362970.77(0.50,1.16)0.2102801.16(1.14,2.28)0.0071481.20(0.76,1.65)0.5702291.38(0.97,1.98)0.0741241.27(0.82,1.95)0.2832531.26(0.90,1.77)0.171 Additive model0.82(2.62,1.08)0.1631.43(1.16,1.76)0.0011.09(0.86,1.40)0.4751.31(1.05,1.62)0.0161.17(0.89,1.53)0.2551.24(1.01,1.53)0.039rs13361707 TT12943Reference60Reference47Reference56Reference35Reference68Reference TC260730.80(0.52,1.25)0.3301831.51(1.05,2.17)0.0271041.10(0.73,1.65)0.6411521.32(0.91,1.93)0.141881.25(0.80,1.97)0.3311681.20(0.84,1.71)0.320 CC101240.66(0.37,1.17)0.157982.08(1.36,3.16)0.001441.19(0.72,1.95)0.495781.71(1.11,2.65)0.015361.34(0.78,2.31)0.290861.55(1.02,2.34)0.040 TC/CC361970.77(0.51,1.17)0.2252811.67(1.18,2.36)0.0041481.13(0.77,1.67)0.5292301.42(1.00,2.05)0.0501241.28(0.83,1.98)0.2572541.30(0.93,1.82)0.125 Additive model0.82(0.62,1.09)0.1711.45(1.18,1.78)0.0011.10(0.86,1.40)0.4511.32(1.07,1.64)0.0121.18(0.90,1.54)0.2401.26(1.02,1.55)0.030rs154268 TT29788Reference183Reference115Reference156Reference90Reference181Reference TC176480.89(0.59,1.33)0.5671311.24(0.92,1.66)0.153701.05(0.74,1.49)0.7941091.18(0.86,1.61)0.299631.12(0.85,1.82)0.2581161.46(0.85,1.82)0.704 CC1740.77(0.25.2.39)0.657272.54(1.34,4.81)0.004101.46(0.65,3.31)0.364212.38(1.20,4.58)0.01061.14(0.43,3.02)0.790252.46(1.28,4.70)0.007 TC/CC193520.88(0.60,1.31)0.5351581.36(1.03,1.81)0.032801.09(0.78,1.53)0.6141301.28(0.95,1.73)0.099691.24(0.86,1.79)0.2531411.19(0.89,1.58)0.240 Additive model0.89(0.63,1.26)0.5081.40(1.10,1.76)0.0051.12(0.84,1.49)0.4491.33(1.04,1.70)0.0251.19(0.87,1.63)0.2891.27(1.00,1.61)0.046rs461404 AA29888Reference182Reference114Reference156Reference90Reference180Reference GA175480.90(0.60,1.34)0.5961311.25(0.93,1.68)0.132711.08(0.76,1.54)0.6681081.18(0.86,1.61)0.383631.25(0.86,1.83)0.2431161.08(0.80,1.46)0.628 GG1740.78(0.25,2.40)0.659282.67(1.42,5.04)0.002101.48(0.65,3.34)0.349222.47(1.27,4.79)0.00761.23(0.58,2.61)0.787262.59(1.36,4.93)0.004 GA/GG192520.89(0.60,1.32)0.5631591.38(1.05,1.84)0.023811.12(0.80,1.58)0.5091301.29(0.96,1.74)0.116691.25(0.86,1.80)0.2401421.21(0.91,1.62)0.187 Additive model0.90(0.63,1.27)0.5321.42(1.13,1.79)0.0031.14(0.85,1.52)0.3731.34(1.05,1.72)0.0191.19(0.87,1.64)0.2761.30(1.03,1.65)0.029^a^Adjusted for age, gender, smoking, drinking, and *Helicobacter pylori* infection; *GCA* gastric cardia adenocarcinoma, *NGCA* non-gastric cardia adenocarcinoma, *Ca*, case *Co* control

Haplotype analysis of polymorphisms in *PRKAA1* {#Sec11}
-----------------------------------------------

The enrolled six polymorphisms locate in the intron or upstream of *PRKAA1*, so these sites may be in linkage disequilibrium with each other. Therefore, the combined susceptibility of these six polymorphisms to GC risk was calculated by haplotype analysis. The results indicated that the haplotype A-G-C-T-C-G (rs6882903, rs10074991, rs13361707, rs3805490, rs154268, rs461404) is associated with the increased risk of GC (OR = 1.29, 95%CI: 1.02--1.62, *p* = 0.035), as compared with other haplotypes (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Haplotype analysis of polymorphisms indicating the susceptibility to gastric cancer risk. The linkage disequilibrium (LD) map according to the genotype data, the color and figure show the linkage disequilibrium coefficient with D' values The prevalence of haplotype A-G-C-T-C-G (rs6882903, rs10074991, rs13361707, rs3805490, rs154268, rs461404) was significantly higher among cases (19.6%) compared to controls (16.2%) (haplotype-specific *p* = 0.035), and those with this haplotype have 1.29 times higher risk of gastric cancer (OR = 1.29, 95%CI: 1.02--1.62, *p* = 0.035) compared to noncarriers

Association between polymorphisms and clinical outcome of patients {#Sec12}
------------------------------------------------------------------

A total 481 patients were followed up for the survival state. The association of polymorphisms with the overall survival (OS) of patients was assessed for their predictive value for patients with heterozygous and homozygous genotype, or their combination, compared to the wild genotype. The results revealed that rs10074991 (AG: adjusted HR = 1.80, 95%CI:1.21--2.67, *p* = 0.004; GG: adjusted HR = 1.75, 95%CI: 1.13--2.70, *p* = 0.012; AG/GG: HR = 1.78, 95%CI: 1.21--2.61, *p* = 0.003) and rs13361707 (TC: adjusted HR = 1.85, 95%CI: 1.24--2.77, *p* = 0.003; CC: adjusted HR = 1.79, 95%CI: 1.16--2.78, *p* = 0.009; TC/CC: adjusted HR = 1.83, 95%CI: 1.24--2.70, *p* = 0.002) were associated with poor OS of patients with NCGC, indicating these two polymorphisms have a significant prediction value for the patients with NCGC, as shown in Table [5](#Tab5){ref-type="table"}.Table 5*PRKAA1* Polymorphisms with clinical outcome of patients with NGCAGenotypeAll patientsNGCAHR (95% CI)*p*-ValueHR (95% CI)*p*-ValueHR (95% CI)^a^*p*-ValueHR (95% CI)^b^*p*-Valuers10074991 AAReferenceReferenceReferenceReference AG1.16(0.87,1.55)0.3001.62(1.10,2.38)0.0151.63(1.10,2.41)0.0151.80(1.21,2.67)0.004 GG1.15(0.83,1.59)0.4011.64(1.08,2.49)0.0201.71(1.12,2.60)0.0121.75(1.13,2.70)0.012 AG/GG1.16(0.88,1.52)0.2901.62(1.12,2.35)0.0111.66(1.14,2.41)0.0081.78(1.21,2.61)0.003rs13361707 TTReferenceReferenceReferenceReference TC1.18(0.89,1.57)0.2531.67(1.13,2.47)0.0101.68(1.13,2.50)0.0101.85(1.24,2.77)0.003 CC1.16(0.84,1.61)0.3641.68(1.10,2.56)0.0161.76(1.15,2.68)0.0091.79(1.16,2.78)0.009 TC/CC1.18(0.90,1.54)0.2461.67(1.15,2.44)0.0071.71(1.17,2.50)0.0061.83(1.24,2.70)0.002rs154268 TTReferenceReference TC1.08(0.85,1.36)0.5251.18(0.90,1.56)0.242 CC1.23(0.78,1.94)0.3671.29(0.78,2.12)0.322 TC/CC1.10(0.88,1.17)0.4051.20(0.92,1.56)0.183rs6882903 CCReferenceReference CA0.97(0.76,1.24)0.7961.12(0.84,1.48)0.443 AA1.48(0.89,2.47)0.1301.56(0.90,2.72)0.113 CA/AA1.02(0.81,1.29)0.8691.17(0.89,1.53)0.252rs3805490 TTReferenceReference TA1.03(0.82,1.30)0.8071.07(0.81,1.41)0.626 AA0.82(0.51,1.31)0.4040.97(0.55,1.68)0.898 TA/AA0.99(0.80,1.24)0.9531.06(0.81,1.37)0.691rs461404 AAReferenceReference GA1.08(0.86,1.37)0.5061.19(0.90,1.56)0.352 GG1.25(0.80,1.94)0.3331.31(0.80,2.13)0.228 GA/GG1.11(0.89,1.38)0.3791.21(0.93,1.57)0.165

Discussion {#Sec13}
==========

This study revealed that *PRKAA1* genetic polymorphismsrs13361707CC, rs10074991GG, rs461404GG, and rs154268CC were associated with increased risk of GC. The susceptibility of these four polymorphisms to the risk of GC were here observed in the subgroup of age ≤ 60, male, NCGC, median to high differentiation and T3-T4 subgroup. Polymorphisms rs13361707 and rs10074991 were associated with poor survival of patients with NCGC.

Variant rs13361707 is located in the first intron of *PRKAA1* at 5p13.1, which was primarily found to be associated with NCGC risk by a GWAS in a Chinese population(1006 non-cardia gastric cancer and 2273 controls, and confirmed with 3288 with non-cardia gastric cancer and 3609 controls) \[[@CR8]\], and the significant association was duplicated by other studies on Chinese population(1124 cases and 1,194controls) \[[@CR14]\] and on Korean population (Kim et al.: 477 case-control pairs; Song et al.: 3245 cases and 1700 controls) \[[@CR15], [@CR16]\]. This study observed that rs13361707 CC genotype was associated with increased risk of GC, and C allele carriers had a higher risk of NCGC, but not of GCA, indicating the association of rs13361707with the increased GC risk is specific to NCGC. Etiological studies have found differences between GCA and NCGC, concerning e.g. *H. pylori* infection \[[@CR17], [@CR18]\], or body mass index \[[@CR19]\], and which was confirmed by epidemiological study that also suggested the susceptibility of genetic polymorphism to GC is different for NCGC and GCA \[[@CR20]\]. Moreover, in the subgroup of positive *H. pylori* infection, our study showed rs13361707CC genotype is associated with increased risk of GC, indicating the interaction of rs13361707 and *H. pylori* can enhance the GC risk, which is consistent with the results of previous study \[[@CR21]\]. The polymorphism rs13361707 is located in the first intron of *PRKAA1* gene, which is a cellular energy sensor maintaining energy homeostasis, and contributes to cancer development by regulating mRNA translation and protein synthesis \[[@CR22], [@CR23]\]. Although the function of rs13361707 is largely unknown, several published studies and the current work indicated that risk of rs13361707 for GC was associated with the type of GC, and its susceptibility may be influenced by *H. pylori* infection \[[@CR5]\].

This study also showed that rs10074991GG genotype is borderline significantly associated with increased risk of GC, and stratification analysis revealed the genotype to be associated with increased risk of NCGC, which is consistent with the reports of Hu et al. \[[@CR20]\] that rs10074991 G allele linked with rs13361707 C allele (these two polymorphisms locate in the intron of *PRKAA1* with the distance of 1333 bp) was a risk factor of NCGC. Moreover, such an association was also reported by Kim et al. \[[@CR15]\] in a Korean population \[[@CR15]\]. However, the function of these two sites remains unclear and the mechanism has yet to be established.

In this study, rs154268 CC genotype was also found to be associated with increased risk of GC for all participants and especially for the subgroup of NCGC, tumor with median to high differentiation, and T3-T4, suggesting rs154268 could be associated with pathological characteristics of GC. Consistent with this, the rs154268 TC genotype was also previously reported to be associated with the risk of GC \[[@CR15]\], indicating that the C allele is a risk factor for GC. Actually, this study revealed the linkage disequilibrium (LD) between rs154268 and rs461404 (D′ = 1.0), which means the result of rs461404 is in accord with that of rs154268. However, to date, there is no functional study regarding the potential functional role of these two polymorphisms in carcinogenesis. In general, in this study, the result of rs461404 was inconsistent with that of rs154268.

The present work showed that rs10074991 G and rs13361707 C allele carriers with NCGC have poor OS, and this association was still observed after being adjusted by basic clinical characteristics (age, gender, *H. pylori* infection, drinking, and smoking) or pathological characteristics (tumor differentiation, tumor stage), indicating these two polymorphisms were independent factors for predicting the clinical outcome for NCGC. To our knowledge, this is the first report to discuss the role of these two polymorphisms in prognosis for patients with NCGC, which however should be verified by a further research with larger samples.

There are some limitations of this study. First, the sample size is relatively small, which may limit the statistical power, especially for the multiple stratified analyses. Second, the polymorphisms discussed in this study were limited in number and based on previous knowledge of potential functional significance of polymorphisms that have been found to be related to GC risk. Thus, a more comprehensive tagging SNP-based approach and a haplotype block analysis would better assesses the association and provides more complete information regarding the associations of AMPK pathway genes and GC risk.

Conclusions {#Sec14}
===========

This case-control study provided the evidence that rs13361707CC, rs10074991GG, rs461404GG, and rs154268CC are associated with increased GC risk, especially for NCGC, and that rs10074991 G and rs13361707 C alleles are independent prognostic factors for NCGC.
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